Hamilton, Erika

Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer

Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., et al. (2020) · New England Journal of Medicine

HER2/EGFR in Cancer ResearchGastric Cancer Management and Outcomes

Cited by 1,326

Targeting HER2-positive breast cancer: advances and future directions

Swain, S. M., Shastry, M., & Hamilton, E. (2023) · Nature Reviews Drug Discovery

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 1,160

Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial

Lin, N. U., Borges, V., Anders, C., Murthy, R. K., Paplomata, E., Hamilton, E., Hurvitz, S., Loi, S., Okines, A., Abramson, V., et al. (2020) · Journal of Clinical Oncology

Brain Metastases and TreatmentHER2/EGFR in Cancer Research

Cited by 544

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

Bardia, A., Krop, I. E., Kogawa, T., Juric, D., Tolcher, A. W., Hamilton, E. P., Mukohara, T., Lisberg, A., Shimizu, T., Spira, A. I., et al. (2024) · Journal of Clinical Oncology

Breast Cancer Treatment StudiesAdvanced Breast Cancer Therapies

Cited by 188

Amyloid-β 11 C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials

Liu, E., Schmidt, M. E., Margolin, R., Sperling, R., Koeppe, R., Mason, N. S., Klunk, W. E., Mathis, C. A., Salloway, S., Fox, N. C., et al. (2015) · Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 151

Antibody-drug conjugates targeting TROP-2: Clinical development in metastatic breast cancer

Shastry, M., Jacob, S., Rugo, H. S., & Hamilton, E. (2022) · The Breast

Breast Cancer Treatment StudiesMonoclonal and Polyclonal Antibodies Research

Cited by 143

VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer

Hamilton, E. P., Ma, C., De Laurentiis, M., Iwata, H., Hurvitz, S. A., Wander, S. A., Danso, M., Lu, D. R., Perkins Smith, J., Liu, Y., et al. (2024) · Future Oncology

Advanced Breast Cancer TherapiesProtein Degradation and Inhibitors

Cited by 116

LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial

Bardia, A., Jhaveri, K., Im, S.-A., Pernas Simon, S., De Laurentiis, M., Wang, S., Martinez, N., Santos Borges, G., Cescon, D. W., Hattori, M., et al. (2023) · Annals of Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 43

COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716).

Vaena, D. A., Fleming, G. F., Chmielowski, B., Sharma, M., Hamilton, E. P., Sullivan, R. J., Shepard, D. R., Papadopoulos, K. P., Patnaik, A., ElNaggar, A., et al. (2021) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersImmune Cell Function and Interaction

Cited by 14